text:
Photos Of Deena Nicole Cortese Getting Out Of Jail!
On Sunday, "Jersey Shore" star Deena Nicole Cortese was bailed out of jail by her parents after being arrested for disorderly conduct in Seaside Heights, New Jersey. Now we have the pictures!
Police arrested the unruly reality star after an officer saw her acting "a little intoxicated." She was spotted standing in the middle of a street and slapping cars that were driving by. We're sure the drivers were very unhappy about that.
If anything, the incident will make some good TV when MTV airs the episode.
Check out photos of the star looking very happy (i.e., a bit drunk) and later more sober with her parents...
You may like
Show Comments ()


text:
See everything on sale inside our Latest Sale Flyer.
Shop Our Sale Flyer
Browse your favorite woodworking catalog!
Shop Our Catalog
Look up product instructions, videos and articles about your favorite tools using our Learning Center.
Join us on your favorite social network! Share your projects and learn from other woodworkers.
Please Note: This item can only be shipped ground to the 48 contiguous states. Some
items cannot be shipped via air due to being flammable, magnetic, contains batteries,
hazardous fumes or where contents are under pressure. Please use a physical address
not a PO Box during checkout.
(No reviews)
Product Information:
Spray a wide range of thin to medium viscosity finishes on cars, boats, planes, wood projects, fencing and more with the Apollo Sprayers ECO 3 Stage Spray System. Features an efficient 3-stage turbine with new dual filter QT Quiet Technology in a thoughtfully designed case to allow full ventilation and air filtration for performance and longevity. Expect more power and pressure than other 3-stage turbine systems in its class.
Includes E5011 Bleed-style 1 Quart Spray Gun and a 20' air hose.
Shipping / Billing Info:
This product ships direct from the manufacturer:
©2016 by Woodcraft Supply LLC

subset: commoncrawl


text:
- Institut Pasteur
- Nous soutenir
- Recherche
- Santé
- Enseignement
- Valorisation
- International
Within a research program that involves three laboratories of the Institut Pasteur (Paris), a post-doctoral position is available for a two-year period in the team of the program leader, Dr. Nicolas Escriou (Viral Genomics and Vaccination Unit = VGVU, Head : Dr Frédéric Tangy). VGVU (UMR-CNRS 3569) develops innovative therapeutic and prophylactic strategies based on the understanding of functional virus-host interactions as well as on the characterization of virulence determinants and their role in pathogenesis. The objective is translational to identify novel antiviral compounds and to develop recombinant vaccines based on the measles vector platform, notably
against AIDS and respiratory viruses.
The program aims at developing innovative antiviral approaches against respiratory syncytial virus (RSV) and rabies virus (RABV) by disrupting virus/virus and/or virus/host protein interactions, with a specific targeting towards the replication complex. The position is funded by the Institut Pasteur to implement new integrative approaches and identify novel inhibitory molecules.
The post-doctoral fellow will contribute to the construction of highly diverse monochain antibody libraries and their screening in infected mammalian cells. He/She will further validate and characterize the antiviral properties of the hits. He/She will interact with each of the program teams and campus core facilities, and will carry out experiments in BSL2 and BSL3 research facilities.
We are looking for enthusiastic, highly motivated candidates, with a solid background in molecular virology. Prior experience with lentiviral vectors, high throughput screening, cell cytometry or in the study of protein interactions, although not mandatory, will be an asset. The candidate should be available from January 1st 2014.
Net salary: around 2,000 Euros per month, depending upon experience.
Please send full CV including research interests and 2 or 3 references with contact information to: Dr. Nicolas Escriou (email@example.com) no later than November 25th 2013.


text:
If I am understanding what you wrote correctly, yes, the point of intersection of the tangents at and intersect on the x-axis.In the derivation of the tangent at P the gradient is found to be 1/p.
To get the tangent at Q, given that P and Q have the same coordinate , I would expect the intersection to be on the x-axis (since is symmetrical). The answer does not confirm this, so that's my first question - why not?
Okay. But q= -p so this is the same asIf I put the coords of Q into the parabola I get:
I therefore take the gradient at Q to be -1/p, then the equation of the tangent follows:
call this equation 1
And, of course, q= -p so this is andThe tangent at P is
subtracting gives
which is the correct answer.
No, it's not a different result. q is still -p, q+ p= 0, and 2a(0)= a(0)= 0. The only "slip" you made was not to replace q by -p as soon as you realized, as you say above, that . Of course, q= p does not give two points so we don't have two tangent to intersect and the whole question falls apart: q= -p.The thing that puzzles me is that to get the answer I am assuming the gradient at Q is symmetrical i.e. -1/p (since the gradient at P is 1/p). Also if I express this gradient as 1/q which is the same thing and substitute into equation 1, I get:
and equation 1 is:
A different result! All these ps and qs are swimming before my eyes. Have I made a slip somewhere?


text:
Will Cops Raid The Pirate Bay?
International authorities aren't easing up in their crackdown on file-sharing ops. There was operation Fake Sweep, in which the FBI busted 16 domains, the high-security shakedown of Megaupload's Kim Dotcom -- and now there's talk that Swedish law enforcement plans on raiding The Pirate Bay.
TorrentFreak, which broke the story, claims that a leaked doc details Swedes' plans to target the world's most important torrent site. This would be the second time that cops have targeted The Pirate Bay: in 2006, they raided the Stockholm offices to shut down the site's servers. The move resulted in the conviction of four associated with the website.
The Pirate Bay, which started deleting torrents on Feb. 29 in an attempt to resist shutdown, found out that cops "have acquired warrants to take action against the site, and expect that both servers and the new .se domain name may be targeted soon."
Here's what's up: Pirate Bay's "well-connected" management heard that Swedish detectives were planning a "move against the site in the future."
Upcoming Events
New York Knicks vs. Cleveland Cavaliers
TicketsWed., Dec. 7, 8:00pm
St. John's Red Storm Men's Basketball vs. Fordham Mens Basketball
TicketsThu., Dec. 8, 6:30pm
New Jersey Devils vs. St. Louis Blues
TicketsFri., Dec. 9, 7:30pm
Never Forget Tribute Classic
TicketsSat., Dec. 10, 12:00pm
Instead of sitting on the info, the operators decided to react with a very articulate "fuck you" to cops -- and post their suspicions publicly on the blog.
Check it out:
"The Swedish district attorney Fredrik Ingblad initiated a new investigation into The Pirate Bay back in 2010. Information has been leaked to us every now and then by multiple sources, almost on a regular basis. It's an interesting read. We can certainly understand why WikiLeaks wished to be hosted in Sweden, since so much data leaks there. The reason that we get the leaks is usually that the whistleblowers does not agree with what is going on. Something that the governments should have in mind - even your own people does not agree.
Since our recent move to a .SE domain the investigation has been cranked up a notch. We think that the investigation is interesting considering nothing that TPB does is illegal. Rather we find it interesting that a country like Sweden is being so abused by lobbyists and that this can be kept up. They're using scare tactics, putting pressure on the wrong people, like providers and users. All out of fear from the big country in the west, and with an admiration for their big fancy wallets.
We're staying put where we are. We're going no-where. But we have a message to hollywood, the investigators and the prosecutors: LOL."
In recent weeks, the Pirate Bay has been conducting efforts to protect itself from law enforcement. After the torrent deletion, it will make its files available via magnet links.
However, it's not clear what a shutdown of the Pirate Bay would do. As Runnin' Scared reported, the end of Megaupload sure wasn't the end of file sharing -- after a brief drop-off, web traffic bounced back with the same vigor as before.
Follow Victoria Bekiempis @vicbekiempis.
Get the ICYMI: Today's Top Stories Newsletter
Catch up on the day's news and stay informed with our daily digest of the most popular news, music, food and arts stories in New York, delivered to your inbox.
In Case You Missed It
Upcoming Events
New Jersey Devils vs. Vancouver Canucks
TicketsTue., Dec. 6, 7:00pm
2016 Jimmy V Classic
TicketsTue., Dec. 6, 7:00pm
Seton Hall Pirates Womens Basketball vs. LIU Brooklyn Blackbirds Women's Basketball
TicketsWed., Dec. 7, 11:30am
Brooklyn Nets vs. Denver Nuggets
TicketsWed., Dec. 7, 7:30pm
Sponsor Content


text:
Monocytic ehrlichiosis in dogs is caused by Ehrlichia canis. A similar disease has been identified in cats in Africa, France, and the United States; however, the exact species causing the infection has not been determined (see Disorders Affecting Multiple Body Systems of Dogs: Ehrlichiosis and Related Infections in Dogs).
Last full review/revision July 2011 by Otto M. Radostits, CM, DVM, MSc, DACVIM (Deceased); Max J. Appel, DMV, PhD; David A. Ashford, DVM, MPH, DS; Stephen C. Barr, BVSc, MVS, PhD, DACVIM; J. P. Dubey, MVSc, PhD; Paul Ettestad, DVM, MS; Craig E. Greene, DVM, MS; Delores E. Hill, PhD; Johnny D. Hoskins, DVM, PhD; Eugene D. Janzen, DVM, MVS; Jodie Low Choy, BVMS; Dennis W. Macy, MS, DACVIM; Dudley L. McCaw, DVM, DACVIM (Small Animal, Oncology); Barton W. Rohrbach, VMD, MPH, DACVPM; J. Glenn Songer, PhD; Richard A. Squires, BVSc (Hons), PhD, DVR, DACVIM, DECVIM-CA, GCertEd, MRCVS; Bert E. Stromberg, PhD; Joseph Taboada, DVM, DACVIM; Charles O. Thoen, DVM, PhD; John F. Timoney, MVB, PhD, Dsc, MRCVS; Ian Tizard, BVMS, PhD, DACVM
Previous: Anthrax in Cats
Next: Feline Infectious Peritonitis


text:
Contact Audrey's: (310) 440-4505
*Zoom in where available by hovering over the image above.
Representing the tree of life, this elegant kiddush cup re-imagines a traditional symbol with contemporary style. Like the branches of the tree, the stem of the cup extends upwards to cradle the wine.
Silverplate and goldplate.
Size: 6" high
Site Powered by UniteU Ecommerce


text:
Sparks flew on 90.3's Sound of Ideas, over the state's decision to cancel plans for a new Mental Health hospital to be built in Mid-town Cleveland.
The official who made that decision defended it on the program, while local mental health advocates called for reconsideration.
Ideastream's Rick Jackson reports
Tracy Plouck has only been Director of the Ohio Department of Mental Health since January, but did not shy away from taking responsibility for the change in plans - which includes not just canceling construction of a new hospital, but closing the current Cleveland facility and transferring its patients to Summit County.
She says her decision is economically sound.
"Consolidating the hospitals at the Northfield Campus now will save at least $4M a year in FY12 and FY13, and that represents operating dollars that I would not have to reduce out of community services."
And, Plouck says, expanding an existing hospital; rather than building a new one, will save 30 million in capital improvements.
But other guests were irritated by the decision, including the Medical Director of the psychiatric ER at Saint Vincent Charity Hospital.
Doctor Leslie Koblentz is among local doctors upset that the thousands of patients who live in Cleveland will not be hospitalized close to home.
"Folks are not comfortable with something that's out of their environment. Clinically, I am very worried about sending patients away. You're taking somebody who is in a crisis period, and now you're going to transport them 15 miles away."
Plus, Cleveland officials say they've already spent more than four million dollars preparing a site on Euclid Avenue for the new hospital.
But Plouck essentially closed the door on maintaining ANY facilities in Cleveland, There is speculation that private facilities could offer assistance - but no one is sure just how `that' would be funded.
To hear the entire program, just click the Sound of Ideas Link.


text:
Save You with My Love
- Artists Materikaa
- Release Date 2012-02-20
- Labels Uniform Beat
- Catalog 7332181045000
Materikaa is a Swedish indie electro pop duo formed in 2011. The band consists of Erik Lidén and Mattias Axelsson. They first met in 2007 and have since then collaborated in different forms. The new music has been recorded both in Stockholm and Gothenburg, starting in the summer of 2011. Their style is influenced by electronic music, dance and pop. The album will be released in 2012 through Uniform Beat / Playground Music.
The first single is called Save You With My Love. It's a strong track based around an intense bass line with a sound for the clubs, still with a fresh melody and beautiful harmonies.


text:
Enter your Email address:
Wolters Kluwer Health may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
your express consent. For more information, please refer to our Privacy Policy.
Leichliter, Jami S. PhD*; Chandra, Anjani PhD†; Aral, Sevgi O. PhD*
Background: Few studies have examined recent temporal trends in self-reported receipt of pelvic inflammatory disease (PID) treatment. We assessed trends in receipt of PID treatment and associated correlates using national survey data.
Methods: We used data from the National Survey of Family Growth, a multistage national probability survey of 15- to 44-year-old women. We examined trends in self-reported receipt of PID treatment from 1995, 2002, to 2006–2010. In addition, we examined correlates of PID treatment in 1995 and 2006–2010 in bivariate and adjusted analyses.
Results: From 1995 to 2002, receipt of PID treatment significantly declined from 8.6% to 5.7% (P < 0.0001); however, there was no difference from 2002 to 2006–2010 (5.0%, P = 0.16). In bivariate analyses, racial differences in PID treatment declined across time; in 2006–2010, there was no significant difference between racial/ethnic groups (P = 0.22). Also in bivariate analyses, similar to 1995, in 2006 to 2010, some of the highest reports of receipt of PID treatment were women who were 35 to 44 years old (5.6%), had an income less than 150% of poverty level (7.5%), had less than high school education (6.7%), douched (7.7%), had intercourse before age 15 years (10.3%), and had 10 or more lifetime partners (8.0%). In adjusted analyses, differing from 1995, women at less than 150% of the poverty level were more likely (adjusted odds ratio [AOR], 2.60; 95% confidence interval [CI], 1.79–3.76) than women at 300% or more of the poverty level to have received PID treatment in 2006–2010.
Conclusions: Receipt of PID treatment declined from 1995 to 2006–2010, with the burden affecting women of lower socioeconomic status.
© Copyright 2013 American Sexually Transmitted Diseases Association
Colleague's E-mail is Invalid
Your Name: (optional)
Your Email:
Colleague's Email:
Separate multiple e-mails with a (;).
Thought you might appreciate this item(s) I saw at Sexually Transmitted Diseases.
Send a copy to your email
Your message has been successfully sent to your colleague.
Some error has occurred while processing your request. Please try after some time.
An Existing Folder
A New Folder
Folder Name:
The item(s) has been successfully added to "".
Login with your LWW Journals username and password.
Username or Email:
Forgot Password?
Enter and submit the email address you registered with. An email with instructions to reset your password will be sent to that address.
Link to reset your password has been sent to specified email address.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Save my selection
Article Level Metrics


text:
Hurdle to speak at chamber dinner
WHEELING – The speaker for this year's Wheeling Area Chamber of Commerce Annual Dinner is sure to be a hit with local baseball fans.
Clint Hurdle, manager of the Pittsburgh Pirates, will give the keynote address for the May 20 event at Wheeling Park's White Palace. A reception will be held at 6 p.m. in the White Palace Ballroom followed by dinner at 7 p.m. Tickets for the dinner are $50 per person for chamber members and $60 for non-members. Tables of 10 can be reserved. For information, call Terry A. Sterling, chamber president, at (304) 233-2575.
Hurdle is a former Major League Baseball outfielder whose 10-year career was spent with the Kansas City Royals, Cincinnati Reds, New York Mets and St. Louis Cardinals. After retiring from playing baseball, Hurdle became a manager. His eight seasons with the Colorado Rockies included leading his 2007 club to the franchise's first National League pennant. On Nov. 14, 2010, Hurdle was hired as the manager of the Pittsburgh Pirates.
He joined the Colorado Rockies organization in 1994 as the minor league hitting instructor, serving in that capacity until he was named the Rockies' hitting coach in 1997. In 2007, Hurdle managed Colorado to its second best finish in the team's 15-year history (only topped by the 2009 season) by winning 13 out of the last 14 games in order to force a tie-breaker game with the San Diego Padres to determine the winner of the National League Wild Card. Colorado defeated San Diego, reaching the playoffs for only the second time in Rockies history. Hurdle's Rockies then beat the Philadelphia Phillies in the Division Series, sweeping them in three games to force a match-up with their rival Arizona Diamondbacks in the NLCS. The Rockies continued their improbable streak by sweeping Arizona in four games to win the first pennant in team history and reached the 2007 World Series where they lost to the Boston Red Sox.
He was hired as the hitting coach for the Texas Rangers on Nov. 4, 2009. In 2010, Hurdle helped the Rangers to their first American League pennant in franchise history before losing to the San Francisco Giants in the 2010 World Series.
After interviewing with both the Pittsburgh Pirates and New York Mets for their vacant managerial positions, Hurdle was hired by the Pirates on Nov. 14, 2010. Hurdle recently agreed to a contract extension, keeping him with the team at least through the 2014 season.
At the 2011 All-Star break, Hurdle had led the Pirates to a 47-43 record, one game out of first place in the NL Central. It was the first time the Pirates had been over .500 going into the All-Star break since winning the 1992 National League East. At the 2012 All-Star break, Hurdle had led the Pirates to a 48-37 record, leading the NL Central division by 1 game over the Cincinnati Reds.
Hurdle is married and has three children.


text:
ASHMORE & CO is an independent privately owned Estate Agency Selling, Letting and Managing Properties in Hendon for 60 years.
The Residential Sales, Lettings & Management departments are run by highly dedicated, experienced and friendly trained staff use their vast local knowledge and expertise to deliver a unique individual personal service which is key to our continued success, growth & development. Due to our commitment, passion and professionalism we have built up a large exclusively loyal client database which includes Local and Overseas Residents, Embassies and High Commissions, Corporate Companies and Local Businesses.
As a forward thinking modern estate agent we use the most up to date technology available so that we can provide for each and every property colour details with colour photographs, floor plans, virtual tours, a place in our rolling screen window display, Home Information Packs (Sales) and inventories (Rentals). We advertise regularly in the local newspaper, we have listings on all the major property websites including our own easy to use website. All our properties are displayed 24/7, 365 days a year! We extensively cover Hendon, West Hendon, Golders Green, Temple Fortune, Colindale, Mill Hill, Mill Hill East, Finchley Central & North Finchley.
5 Finchley Lane, London, NW4 1BP


text:
You are here
FSLH to Host Summer Medical Camp for Teens
Communications Specialist
(315) 624-5602
Faxton St. Luke's Healthcare will host a two-day medical camp for teens ages 15 through 18 on Thursday, July 17, and Friday, July 18, 2014, from 8am to 3:30pm. MediCamp seeks to demonstrate to teens how a hospital operates and provides them with the opportunity to explore different departments for potential career endeavors.
Registration is $25 per student which includes scrub tops, breakfast and lunch for both days.
All interested students are required to submit an application by Monday, June 30, 2014, including a brief essay explaining why they are interested in healthcare and what their goals are for participating in the program.
Attendance is limited to 14 participants. All applications submitted within the application deadline will be reviewed for acceptance into the program. Participants will be notified by email of their acceptance by Monday, July 7, 2014.
If you are interested in participating in MediCamp, please visit www.faxtonstlukes.com/medicamp to print an application or call Amy Weaver at (315) 624-6579 for more information.


text:
Concerns Mount Over Future Of Mill
Clifton-Fine Economic Development Corporation President Chris Westbrook is worried what the future holds for the idled Newton Falls paper mill and what will happen to the industrial site if the equipment is removed by its owners.
"I think there's a lot of other environmental liabilities that are going to have to be dealt with and I'm afraid that they're just going to walk away and we're not going to be able to hold them responsible for those environmental liabilities," said Westbrook.
Friday, December 9, 2016, Watertown, NY
On Wall Street


text:
Avoiding Train wreck User ExperiencesA UX train wreck is a user experience that makes you work- really work. UX that's so broken, it breaks you down psychologically or emotionally. In this post we'll explore some big trainwreck user experiences from Apple, Amazon, Google and Microsoft. These companies do a lot of great UX work, but they also do some 'train wreck' ones that make for good learning. Do the opposite of these and you'll end up closer to an elegant user experience.
August 16, 2013-->
Designing for the multi-user: missed by Apple, Google and othersThe iPad is a multi-user device according to industry reports. But you wouldn't know it from picking up even the latest generation iPad, especially if you are a physician or business user handling sensitive data. The design approach of designing for lone users misses out on a fundamental nature of mobile devices: they are social. To design for the multi-user is to recognize this need for delivering a rich social user experience. Work-arounds to accommodate...
May 01, 2013-->
Are your users dumb or are your designers the dummies?Stupid userIn this post, we'll explore the basic user experience skill of not taking for granted what your users can do. Why is this important? If your assumptions about your users are incorrect, you'll make unwise design decisions...and you'd never want to do that now, would you?!
March 19, 2013-->
Does it take Einstein to design for the most important task?It was Albert Einstein's birthday yesterday, and to celebrate I wanted to share this excellent example of outstanding task-oriented design from Einstein Healthcare Network. What makes me dedicate an entire blog post to Einstein.edu's home page? The courage that I believe is reflected in the home page layout choices.
March 15, 2012-->
March 02, 2012-->
Should your UX person act as Product Owner in Agile?The Agile development Product Owner role is strategically suited to be owned by the User Experience team or person supporting the project. Since a PO carries a great deal of responsibility, it may be more prudent to share the role with the UX, thereby offering shared control and collaboration- a key feature of Agile team organizations.
February 28, 2012-->
Get ready for these new User Interface innovationsCity Wall 3D interfaceThe annual Consumer Electronics Show (CES) 2012 just wrapped up in Las Vegas and while word has it there were not many surprises, user experience (UX) and new user interfaces (UI's) were an underlying theme. It's good to see UX on the brain: It shows it is becoming widely understood that the key to user adoption with new technology demands a calculated obsession about your user experience. So what trends and themes can you take away from this year's CES on the user interface front?
January 14, 2012-->
Does Agile move too fast for Usability?Agile's defining characteristic is speed. Unlike other software development methodologies (like Waterfall) that work in timeframes of months, Agile timelines are measured in weeks (2-4 typically) with actual code developed for each 'sprint'. Is Agile's rapid and fixed development deadlines and deliverables conducive of usability activities? In short
September 30, 2011-->
Social Circles- the beginning of the intelligent social interface?The recent release of Google's social circles (part of the new 'Google +' social network) is particularly exciting since I think it constitutes a social interface that accounts for real-world considerations.
July 08, 2011-->
10 years in pursuit of exceptional user experienceExperience Dynamics celebrates its tenth birthday this year. It was Spring of 2001 that Frank Spillers founded Experience Dynamics together with Alison Gavine. In this post come with me on a stroll through our high points, the industry and the road ahead. We've been determined from the beginning to deliberately stay focused on the cognitive and emotional aspects of user experience (the stuff that really matters in design) over the draw of offering development or...
June 29, 2011-->
Figuring out how to deal with Stupid UsersThere's a common belief that the problem with errors users make with Web sites or Web apps has to do with differing intelligence levels.Some users even blame themselves for being dumb. "Sorry about this", I was told by an IT manager at a major financial institution, "It's just that our users are lazy and stupid". If only, we could blame intelligence, IQ or motivation! Waiting for smart users to use your design is like trying...
May 27, 2011-->
Is your design Evolutionary or Revolutionary?Sometimes some of the best usability advice comes from users directly. In some recent usability testing, a user said something which I found very perceptive.
March 22, 2011-->
My top 3 User Experience Blog posts of 2010If you read nothing else on Demystifying Usability last year, read these top 3 blog posts from 2010...
January 26, 2011-->
User Experience Calendar 2011- shipping now!I'm happy to announce our new User Experience Calendar for 2011 is ready to ship!
November 20, 2010-->
Design technique: use containership to shape user experienceContainership is a useful design technique that can help you direct your user's attention and shape their experience.
October 27, 2010-->
Design and Emotion: Designing for MoodMost of the Design and Emotion community focus is on emotion and bypasses mood. The main reason is that emotion in design can be measured, mood is not so easy. However this doesn't excuse the lack of effort- mood is as powerful as
September 27, 2010-->
Do top and bottom Web page toolbars add Clutter?In the past few years toolbars have started to appear on popular social networking websites like Facebook; product review sites like CNET; news sites like Reuters and the Huffington Post and social tool services like HootSuite. Today, it seems more Web page-level toolbars are inhabiting our screens. The result: less control of the web page, the session or the redirect experience...and a more cluttered web browsing session.
August 26, 2010-->
New Study- Gender differences in Web UsabilityComscore just released a new study yesterday (June 30 2010) entitled Women on the Web: How Women are Shaping the Internet. The worldwide study adds some key insights into the growing research on gender differences on the Web and in particular around social networking usage. Why is this a big deal?
July 31, 2010-->
5 Task-Centered Design Patterns Competitors are Employing to Out-gun Your DesignHow well you get your customers to their destinations with your design, and help users do what they need to do, is the difference that makes a difference in customer experience. If you are not doing it well, I guarantee you your competitors are or are trying to find a way to. In this post, I'll cover 5 strategic patterns that you need to lead the pack. What is Task-Centered Design? Task-Centered Design or Task-Oriented...
June 28, 2010-->
Facebook's Privacy FAIL: Lessons for Designing Privacy in Social NetworksFacebook has dominated the tech news this month since their April 2010 launch of the Open Graph. The problem stems from the new platform changes extending Facebook's ongoing bad habit of violating users actual or perceived privacy. Facebook's problem with privacy has been both a business and a design problem. Today, Facebook held a press conference announcing major changes to their privacy policy in addition to what looks like a significant change in Facebook leadership's...
May 26, 2010-->
5 Problems with Borrowing Design Ideas from Apple (and others)"Imitation is the highest form of flattery"...so the saying goes. The problem with borrowing design and user interface metaphors from other applications, websites or brands is that what works in one place might not work in another. In this post we'll look at the pitfalls of copying design elements from other designs and what to do instead.
March 18, 2010-->
Happy Birthday Dr. Seuss! (usability ode to the good doctor)Today is Dr. Seuss's birthday! Originally written in 2001, this is still timely and captures the consequences of poor user experience:
March 02, 2010-->
The Science of Fun: How Fun Helps Improve Your DesignFun is important to design usability (Monk et al 2002; Overbeeke et. al. 2002; Hazzenzahl and Burmester 2001). Fun activates several important cognitive processes, known for centuries from games we have created and played. Think of a fun game you lasted played...These same processes make fun an important design usability tool.
January 07, 2010-->
User Experience Calendar for 2010...Just Released!Over at Experience Dynamics, we have just released our brand spanking new User Experience Calendar for 2010! The calendar has a theme for each month (14 months total) with a short usability meditation providing inspiration, food for thought and some some important concepts for those minding the user experience.
November 30, 2009-->
Making Things Easier with Tablet computing?In summary, I am optimistic that the next generation of tablets will bring better user experience. To achieve this goal, focusing on the total tablet user experience will be crucial. Hardware and software, tablet and regular computing interfaces will have to dance around each other, sensing the user's needs. I don't think this is rocket science but it will require addressing the issues raised above. With Apple competing in a once Microsoft-only space, it should get interesting.
November 04, 2009-->
The Real-Time Web- thoughts on delivering the Real-Time user experienceOn of the interesting developments in content delivery for the Web is what's being called the "real-time" Web. The implications for user experience design are substantial.
September 23, 2009-->
What's next in mobile user experience? Augmented RealityA recent spate of game-changing applications for mobile devices have been emerging over the past few weeks and months. Their defining characteristic? Real-time global positioning providing helpful data overlays, or so-called Augmented Reality displays.
September 09, 2009-->
7 Steps to Avoiding User Adoption Problems with Site RedesignsWhen you redesign a new site, how do you know users are going to like it? How can you ensure that you know how the redesign will sit with existing as well as new users? Earlier this year, Facebook faced this dilemma when 1.7 million of their uses started a group called Petition Against the New Facebook. The purpose of the group was to boycott the redesign changes Facebook unleashed upon its users: "I dislike...
August 27, 2009-->
Privacy: your biggest user experience challenge"We are all in the privacy business". This was my general conclusion when working on next generation usability for the popular directory look-up portal whitepages.com website (used by 200 million adults in the US). It doesn't matter what your website does online, if it involves giving consumers information, you are in the privacy business first and foremost. What does this mean? Privacy is one of the biggest concerns users bring to the Web experience. It...
July 09, 2009-->
How relying on 'user education' is a failed strategyMaybe you have heard the saying "we'll take care of that in user training". The notion that problems users have can be resolved by user training is severely flawed. Yet entire departments rally around this belief and worse many companies seem to wrap product management around it. The idea that you can educate users about how to use a user interface is misguided. The goal of usability is to create intuitive user interfaces. Intuitive means...
April 06, 2009-->
Competitor designs: The danger of borrowing across contextsThe Internet is great for taking a rapid look at what your competitors might be doing as you design a user interface. While this is a valuable learning opportunity, it can also be dangerous and inappropriate for your design. The biggest problem I have found, is that user interface approaches or design elements do not carry neatly across contexts. Each design context is unique. By design context I mean a few things: Brand experience: Each...
February 19, 2009-->
President Obama: Vision for Usability?Usability awareness back in the White House? Obama is already being described as the Internet President. Will his Internet savvy include an agenda for usability? If so, what might that agenda include? In this post I explore these questions, connect some dots and present some potential solutions for how Obama's technology goals are linked deeply to harnessing usability best practices. Tech innovators get excited Late in the election season, Silicon Valley expressed its joy that...
January 27, 2009-->
Intro to Emotion Design- Pleasurability and Emotional DesignHere is a recording from a live usability seminar I gave a few weeks ago on the topic of emotion design and pleasurability. (Sign up at the bottom of that page to our usability research newsletter to be alerted to upcoming free usability seminars like this)... In the age of the iPhone, emotion in design is heating up as a competitive differentiator. Products that deliver a compelling and elegant user experience are characterized by their...
January 04, 2009-->
December 16, 2008-->
8 Things you need to know about improving online experience- new studyA new study (July 2008) entitled 'Factors that Improve online experience' by Sathish Menon and Michael Douma from the Institute for Dynamic Educational Advancement offers key insights on the current state of online user experience. The study reinforces known usability truths, sheds light on user perceptions but more interestingly points to disconnects between designers and users. The study surveyed perceptions, expectations and practices across various audiences and contrasted the results. The key findings and what...
August 28, 2008-->
What color do you like? The usability of look and feel (strategy with icons, images, branding elements)The graphical or visual aspects of an interface are the most easily recognizable. They require no methodology (Graphic design vs usability) or design distinctions, (What is design?). Everyone from CEO to programmer can understand an interface by it's visual treatment. For some the interface is "eye-candy" and for others representative of organized emotional response and visual perception. Oftentimes, the confusion over who dictates the design can lead to confusion and often a gratuitous use of...
June 18, 2008-->
Design Like You Give a Damn!- Sustainable DesignDesign Like You Give a Damn is the name of a really great book on architectural responses to humanitarian crises. The book details design projects around the world from the ecologically dry toilet to the hippo water roller. Sustainable design is also the theme of an aerial dance and acrobatics show my daughter plays a part in that's premiering in Portland this month, called ¡Entusiasmo!, a true story of Gaviotas, Columbia. The show is written...
May 26, 2008-->
"Forcing functions"- interaction design technique, used but not widely understoodWhat is a forcing function? A forcing function is a constraint where the user "is forced" to complete a task based on a limited, paired down set of features or controls. Forcing functions help streamline, simplify or minimize how a user interacts with a design. Designers benefit from this interaction design technique by reducing navigation redundancy, task effort and the complexity caused by "feature frenzy" (see my previous article on feature creep). Not all forcing...
April 28, 2008-->
Warning: Third-party Usability is Bad for your HealthThere is a huge problem in the software and web services industry: 3rd party applications, widgets, dashboards or site add-ons can kill your usability efforts. Poor user experiences with 3rd-party applications can undermine or make your usability efforts look bad. Vendors such as PeopleSoft, Vignette and many others are notorious for providing "clunk-ware", "vapor-ware" or "sneaker-ware" as one of our clients at Experience Dynamics put it. Let's explore why this is a major problem that...
March 21, 2008-->
AJAX Usability Checklist (Free holiday bonus for our readers)This Ajax Usability Checklist is a bonus guide that accompanies my AJAX Usability Seminar, I am offering it in the form of this post as a bonus for readers- thanks for your support! The Web is changing fast. New standards are emerging, new approaches to coding such as Scriptaculous, AJAX, Ruby, Flash/Flex, Silverlight and others are creating a leap-frog situation where many new websites, web apps and portals are implementing next year's User Interface elements....
December 24, 2007-->
What is Design? (Yes, all 10 definitions!)When the term design is used it can mean many things, depending on who you are and which conversation you are having. Rarely do people stop to compare 'mental maps' and clarify which type of design they are talking about! I believe this has to do with the multiple definitions of design and the lack of awareness of each specific type of design, its function and timing in a process. The other factor being how...
October 30, 2007-->
Multi-modal design: Gesture, Touch and Mobile devices...next big thing?It's great to see excitement building for the Apple iPhone (launch expected late June '07). Korea's LG Prada, an iPhone competitor product, launched a few months ago in the UK. Just this week a new touch screen device- Taiwan's HTC Touch was announced for release immediately in the UK and later this year in the US. The hot attraction of course with the iPhone, the Prada and the Touch is that they offer touch and...
June 05, 2007-->
Is Google's business model Progressive Disclosure??Quick Google user, you need to look up a measurement; phone numer; UPS tracking code; address; mathematical formula ..."Didn't you know Google had a tool for that?" Yes, Google has a tool for everything these days it seems, but it's not a consistent tool kit. Sometimes you get it and oftentimes you don't. Is that why Google doesn't promote what I call their "world of widgets" (WoW's)? How is it some people know the secret...
February 19, 2007-->
"Feature frenzy"- 10 tips to getting feature creep under controlWhy the (feature) frenzy? Historically, marketing says "software sells with more features" (or perceived features). There is a psychology (especially true in the United States) that the more you get when you buy something, the better the purchase decision. Unfortunately, added 'bells and whistles' might feel like a better deal, but can turn into a nightmare when you (or your user) sit down with the software and use it. A few words about features Features....
February 02, 2007-->
Is Usability a Public Relations problem?It will be if you don't do something about it. At Experience Dynamics, (a Portland, Oregon usability consultancy) we recently helped one of our Fortune 10 clients with some usability testing on a product that was actively being improved for usability. The client pointed us to a blog entitled "Worst Experience Ever" where the blogger recited his experience with the actual process the program manager was interested in usability testing. This blogger's posting had drawn...
January 02, 2007-->
Personas LIVE! Transcript- Interview with Frank Spillers, Tamara Adlin and John PruittThe following is a transcript of a live interview with Persona book authors John Pruitt and Tamara Adlin, conducted by Frank Spillers in October 2006. This seminar is available with the slides and audio presentation here (requires brief registration, privacy protected). Transcript of Personas LIVE!: This interview follows the publication of Adlin and Pruitt's personas book, "The Persona Lifecycle : Keeping People in Mind Throughout Product Design"- published earlier this year... Frank Spillers Welcome... For...
December 05, 2006-->
Usability Testing methods- What are we observing and why? (World Usability Day 2006 Event)Next week is World Usability Day, a day when the usability community gets out to raise awareness and visibility about the field and goals of usability engineering and user centered design. "World Usability Day 2006 promotes the value of usability engineering and user-centered design and the belief that every user has the responsibility to ask for things that work better". (from the WUD site) Here are a couple of items related to World Usability Day...
November 09, 2006-->
What is Emotion Design? (A practical definition)Two years ago, after returning from the Design and Emotion conference, I shared an extensive post on Emotion Design, a topic that has a lot of potential to open up new conversations about user experience and usability. This week, the fifth conference, Design and Emotion 2006 takes place in Göteborg, Sweden. Since I wanted to attend the conference this year but couldn't, here is a practical definition of design and emotion that I hope you...
September 26, 2006-->
The Importance of User Experience- the Poster!The Importance of User Experience Here's a poster that reflects some thoughts about user experience...all of the bottom row items (outcomes of positive user experiences) in the poster are based on empirical research. Let's review some of that research, a brief glimpse at the science behind what the poster is communicating... About the poster project and translations into many languages below all these quotes (bottom of the post)... Elements that contribute to a positive user...
September 21, 2006-->
Designing for the "Average User"User advocacy is one of the central goals of usability. User advocacy can be defined as the process an IT professional (with an interest in user experience) goes through in re-sensitizing herself to the world of the "average user". Usability expert reviews are largely an exercise in user advocacy, in addition to an analysis of known usability issues and problems based on knowledge of User Interface Style Guide abnormalities. So. why do we forget about...
April 21, 2006-->


text:
ASSIST Training
Friday, April 5 - Saturday, April 6, 2013
Participants will be trained as a first responder for crisis situations in this two-day seminar. Don't miss out on this wonderful opportunity for a great price, even for non-CSI members! There are only 30 slots available so sign up fast!
- Hosted by:
- Chi Sigma Iota
- Location:
- Classroom Building - Room 258
- Cost:
- Free for CSI members/$20 for non CSI members
- Audience:
- Current Students
- Liz Linstad firstname.lastname@example.com


text:
- Worldwide Rank #1,066,123
- Follower/Following Ratio 1.57
- Daily New Followers 1
Yuri Quintana Twitter Stats
@yuriquintana - Tracking Yuri Quintana Twitter profile since April 3, 2014
Global innovator, Harvard HMS, Global Health, Bioinformatics, eHealth, eLearning, Social Media, mhealth, Online Communities, Systems Engineer. Views are my own.
Boston, MA
Yuri Quintana Tweets
@yuriquintana has posted 301 tweets in the last 30 days, which translates to an average of 10.0 tweets per day.
Yuri Quintana Twitter Followers
@yuriquintana has 5,737 followers on Twitter.
This account is #1,066,123 in the worldwide rank of the most popular Twitter users.
Yuri Quintana Following on Twitter
@yuriquintana is following 3,651 Twitter accounts.
Last month this account followed 389 users.
Yuri Quintana Predictions & Milestones
@yuriquintana will hit 5,867 followers in the next 3 months, and 6,264 in one year.
You are on Yuri Quintana's Twitter stats page
We track these Twitter stats since April 3, 2014 . You can see how many followers Yuri Quintana lost or gained and what the prediction is for tomorrow or the next 15 days, together with all kinds of other stats like rank compared to all Twitter users, tweets etc.
Why don't you give it a try and compare Yuri Quintana to yourself ? Or if you are Yuri Quintana get even more feature rich & up-to-date stats with our premium Twitter Stats.
Twitter Counter is the #1 Twitter stats site powered by Twitter. It all started in June 12, 2008 and we grew rather rapidly because of our Twitter Counter badge. The button is a nice small image that shows your visitors how many followers you have on Twitter. Within a year the button was on many many blogs around the world and we displayed more than 100 million buttons in one month. We track follower stats for over 180 million users now.


text:
Open Knowledge Foundation
In the past 2 years we have seen an explosion in the availability of freely reusable, machine readable data from public bodies and increasingly easy to use tools and services to analyse, represent and deliver this data. How is this data having an impact on journalism? How can journalists use data to create better reportage? What are the limits of public data sources? A panel of leading journalists and researchers present their work and tell us what they think is next for data journalism.
June 30th from 14:00 to 15:30 Track II, Panel with contributions from
Simon Rogers, Guardian Datablog (UK)
Stefan Candea, Centre for Investigative Journalism (Romania) + Nieman Fellow (US)
Caelainn Barr, Bureau of Investigative Journalism (UK)
Federica Cocco, OWNI (France)
Liliana Bounegru, European Journalism Centre (Netherlands)
Paul Bradshaw, Help Me Investigate (UK)
Mirko Lorenz, Deutsche Welle (Germany)
Followed by a panel discussion moderated by Michelle Thorne, Mozilla Foundation.
Simon Rogers is editor of the guardian.co.uk/data (datablog, @datastore), an online data resource which publishes hundreds of raw datasets and encourages its users to visualise and analyse them. He is also a news editor on the Guardian, working with the graphics team to visualise and interpret huge datasets. He was closely involved in the Guardian's exercise to crowdsource 450,000 MP expenses records and the organisation's coverage of the Afghanistan and Iraq Wikileaks war logs. Previously he was the launch editor of the Guardian's online news service and has edited the paper's science section. He has edited two Guardian books: How Slow Can You Waterski and The Hutton Inquiry and its impact. In 2010, Simon received a special commendation from the Royal Statistical Society in its awards for journalistic excellence. His Factfile UK series of supplements won a silver at the Malofiej 2011 infographics award and the Datablog won the Newspaper Awards prize for Best Use of New Media, 2011.
Stefan Candea, a member of ICIJ (icij.org), is a freelance journalist and co-founder of the Romanian Center for Investigative Journalism. He has won several awards including the IRE Tom Renner Award and the Overseas Press Club of America Award. He reported on the connections between international organized crime networks and high-ranking politicians and public servants, covering the international arms trade, illegal international adoption, the separatist region of Trans-Dniester and the diamond business in Romania. He teaches investigative journalism at Bucharest University and was a 2011 Nieman Fellow at Harvard University.
Caelainn Barr is a journalist specialising in EU investigations at the London based Bureau of Investigative Journalism. The Bureau a not-for-profit organisation which aims to bolster original journalism by producing high-quality investigations for press and broadcast media. She has worked on an award-winning, nine month investigation with the Financial Times into EU structural funds, a data based analysis of Commission expenditure and continues to look at all aspects of EU legislation and expenditure. These investigations have been the subject of lengthy reports in the Financial Times, the Guardian, the Telegraph, Al Jazeera's People and Power, BBC's Newsnight and File on Four.
Federica Cocco was born in Cagliari, Sardinia. She was educated in Italy, the United States and England and currently works in Paris as editor in chief of Owni.eu. In the past, she worked for Amnesty International, the United Nations Refugee Agency, the Centre of Investigative Journalism in London and Wired Italy and UK. Since she joined the newsroom last year, OWNI won the Online News Association award for excellence in journalism and was selected as a finalist at South by Southwest.
Liliana Bounegru works for the European Journalism Centre (EJC), an independent, international, non-profit institute dedicated to the highest standards in journalism, primarily through the further training of journalists and media professionals. She coordinates work on data-driven journalism, and, together with Mirko Lorenz (Deutsche Welle), organised one of the first international events on data-driven journalism in 2010, bringing together leading practitioners from around the world. She is also a Research MA candidate in Media Studies, University of Amsterdam. For more see lilianabounegru.org.
Paul Bradshaw is visiting professor in online journalism at City University London and Course Leader of the MA in Online Journalism at Birmingham City University, which he established in 2009. He is best known as the publisher of the Online Journalism Blog, described by UK Press Gazette as one of the country's "most influential journalism blogs" and by the Telegraph's Shane Richmond as "The UK's Jeff Jarvis". He is also the founder of the investigative journalism crowdsourcing site Help Me Investigate, which was shortlisted in 2010 for Multimedia Publisher of the Year.
Mirko Lorenz is an information architect, journalist and trainer. His focus is on digital publishing, storytelling and multimedia content management systems. He is a member of the Innovation Projects team at Deutsche Wellle and editor for Visioncloud.eu.


text:
Well I'm easy going person who loves movies and music. My newest thing I love to do is going to the gym and working out with my personal trainer three times a week. It's so great to see how the body changes. Great motivation.
If u want to know more just ask. I'm friendly.
Other then working focusing on toning up and from achieving that goal maybe start competition
Well prob now my new gym body would be the next thing someone notices about me. But I'm not changing my character because of the image factor. I'm still a good person
Great food
My bed
My car
Second guys if you like my profile say hi cause I can't see if you like me


text:
Arsene Wenger can cross off another striker off his summer transfer target list with AC Milan forward Stephan El Shaarawy understood to be on the verge of signing a long-term deal to stay at the club.
20 year-old El Shaarawy started his career at Genoa and had an impressive loan spell at Serie B side Padova before AC Milan snapped him up in 2011. The striker has established his first team place at Milan, starting in each of their 24 Serie A matches this season. He has netted 17 goals for Milan this season and Wenger was planning a swoop for the prolific Italy international this summer.
The Gunners manager had openly admitted his interest in El Shaarawy but TalkSPORT revealed that the player has agreed in principle to a new deal that would keep him at the San Siro till 2018. Milan have purchased Mario Balotelli just weeks back and the Italian duo are expected to form a powerful strike pairing over the years to come.
The new deal could bump up El Shaarawy's asking price to £35 million and Wenger is unlikely to shell out that much money for a player this summer. Fiorentina's Stevan Jovetic and Barcelona's David Villa remain options for the manager and they would cost him significantly less when he seeks to reinforce his attack at the end of the season.


text:
We are strongly committed to safeguarding our visitors' privacy on PatrickSmithOnline.com. We operate under the following strict privacy policy:
The only information we obtain about our customers is information we need to process credit card charges for subscription fees. The information collected is never revealed, sold, or made public for any reason.
Personally identifiable information provided by subscribers (name, email or home address, etc.) is never disclosed to any individual or business.
External Links
In order to provide visitors with greater value, some of our pages may provide links to various third party websites. In no case is subscriber information or 'cookies' provided to the third party sites.
However, keep in mind that many sites do attempt to capture visitor information when you browse those sites. Once you leave our site, we are not able to alert you should another site attempt to gather information from your browser.
We use a variety of security measures including encryption and authentication from Thawte to protect the loss, misuse and alteration of your personal information under our control.
Our site gives users the opportunity to opt-in to receive communications from us. You can be assured that we never reveal, sell, or make available your email address to anyone for any purpose. This site also gives users options for removing their information from our database in order to stop receiving our communications.
© 2007, Panorama Studios. All Rights Reserved


text:
Sam Cooke "The Best Of Sam Cooke" (180gm Vinyl 2LP Remastered At 45RPM)
Sam Cooke – The Best Of Sam Cooke
" The Best Of Sam Cooke " 180 Gram Vinyl 2LP Set REMASTERED At 45RPM.
A Groundbreaking Soul Pioneer and An Influence On Generations of Singers – Everyone Agrees Sam Cooke Is The MAN! 180 Gram 45rpm Audiophile Reissue!
"…He had an incomparable voice. Sam Cooke could sing anything and make it work. But when you're talking about his strength as a singer, range is not relevant. It was his power to deliver — it was about his phrasing, the totality of his singing," – Van Morrison, for Rolling Stone magazine's 100 Greatest Singers Of All Time, ranking Cooke at No. 4
This Best Of Sam Cooke album was the beacon that kept Cooke's most popular songs in the public eye. Between 1957 and his death seven years later, Cooke recorded an average of one Top Ten single every four months! And now on this single LP, you can relive the timeless best known and best-loved Sam Cooke classics.
"You Send Me", "Only Sixteen", "Wonderful World", "Chain Gang", "Cupid", "Having a Party" And more!
For a couple of generations this was the first – and often only – Sam Cooke album they owned. Although there are more ambitious collections that show Cooke's remarkable range and diversity, this is still the best starting place. These are Sam Cooke's biggest commercial hits. This is the message in a bottle that brought his gifts to millions of people.
What is it that makes Cooke's music so irresistible? Well, first the voice, of course. So good, in fact, was Cooke as a vocalist that Atlantic Records vice president Jerry Wexler said matter-of-factly, "Sam Cooke was the best singer who ever lived, no contest." But beyond just his voice, it's the phrasing that makes these songs so timeless and memorable. Cooke himself explained it this way: "You just talk the story. That's how you get people to come to you – because it's not like a song, it's like two people rapping, only with a melody attached. But then when you come to the hook ('That's the sound of the men working on the chain gang'), then you're free, everybody's gonna sing that part, you want to get everybody to sing along." And they're still singing along.
So we all know the songs. We all know they're great. But nobody's known — not unless you were there when it was recorded — just how incredible these recordings actually sound. Now, cut at 45 RPM with every detail tended to and no expense spared, we've got The Best of The Best of Sam Cooke.
• 45rpm 180g Vinyl
• Double LP
LP1 – Side 1:
1. You Send Me
2. Only Sixteen
3. Everybody Loves To Cha Cha Cha
1. (I Love You) For Sentimental Reasons
2. (What A) Wonderful World
3. Summertime
1. Chain Gang
2. Cupid
3. Twistin' The Night Away
4. Sad Mood
1. Having A Party
2. Bring It On Home To Me
3. Another Saturday Night (Alternate Take)


text:
- Font:
- +
- -
Some Jenna Elfman fans were startled by what the star had to say in a recent issue of Scientology's magazine Celebrity.
The former star of "Dharma and Greg" is a devotee of the controversial religion, whose members also include Tom Cruise and John Travolta.
"I intend to make Scientology as accessible to as many people as I can. And that is my goal," Elfman said. To do this, she says, it is my "duty to clear the planet." By "clearing" she means to rid the world of "body thetans" — aliens who Scientologists believe inhabit the earth from a nuclear explosion 75 million years ago. She continued that "the more successful I became, the more suppression I bumped into … especially in the entertainment industry, which really is home to rabid suppression."
"Her comments seem to reflect an increasingly almost paranoid view of the world around her in which she appears to have cleared house of all the suppressive people," Rick Ross, who runs Cultnews.com, tells The Scoop. "Which to Scientologists would include all the people who are critical of Scientology."
What's my age again?
Gastineau is starring in the reality show "Gastineau Girls" for E! with her 20-year-old daughter Brittny, and some promos have said that she's 40.
But back in 1991, when she was getting a divorce from former New York Jet Mark Gastineau, she was identified as being 31 — which would make her closer to 44 or 45.
When presented with the equation, a spokeswoman for E! quipped: "Lisa is 42 if Brittny is 22."
Notes from all over
Sounds like Uma Thurman is wrestling with balancing her career and motherhood. "It is really impossible," the "Be Cool" star told DarkHorizons.com. "Actually my ex-husband said to me the other day that I clearly was someone who wanted to be a full-time mother and still wanted to be an actress and I kept insisting I could do it, but I couldn't. I really try to give all of myself. I mean things this year I have been really lucky, and I refuse to read a script that didn't shoot in New York City, because I just needed to be home. It is a very difficult balance, and I have even thought about quitting, but then I think I can't quit, because I love what I do so much and it is the wrong signal and now I am a single mother so I really can't quit." . . . Madonna spent most of her time on the set of the Material Girl video smooching with Keith Carradine, director Mary Lambert recently revealed. . . . Donald Trump has become an anti-smoking advocate, and even saying it should be censored in movies. "Let's stop the smoking," Trump says. "Let's not show smoking in movies. And if they do, let's not let the kids see it."
Notes from all over
Jeannette Walls Delivers the Scoop Mondays through Thursdays on MSNBC.com
© 2013 msnbc.com Reprints


text:
Chris Martin's voice is like a sucker punch to the heart. The second a Coldplay song comes on, it's feelings everywhere.
To prove that Chris's dulcet British tones can inject emotion into anything, iHeartRadio created "Emotional Objects with Chris Martin," a challenge to the Coldplay frontman to sing about a pre-selected grab bag of the most random objects, including an old shoe, an overripe banana, and a BlackBerry, "the saddest tale of all."
See if your eyes don't well up with longing for the days of raised Q10 keyboards—we dare you.


text:
Leland Stanford MacPhail Sr.
Born: February 3, 1890 in Cass City, MI
Died: October 1, 1975 in Miami, FL
Inducted into the Hall of Fame by Veteran's Committee as Pioneer/Executive in 1978.
View Larry MacPhail Page at the Baseball Hall of Fame (plaque, photos, videos).
View Player Bio from the SABR BioProject
About biographical information
Let people know you like this site. Sponsor this page for $10. Your message will replace this ad.
BR Bullpen: Find or enter more info for this person (what's this?)


text:
Invisible Oil Plume?
The oil is there, at least 22 miles of it. You just can't see it.
A lot of the crude that spewed from BP's ruptured well is still in the Gulf of Mexico, but it's far below the surface and invisible. And it's likely to linger for months on end, scientists said Thursday in the first conclusive evidence of an underwater plume of oil from the disaster.
The crisis is not over, people.
But wait… as Commodity Surge points out:
the alleged 21-mile long oil plume, identified by the Times as "new research," and the Post as "evidence" of the oil still lingering in the Gulf or some unknown location in the vast seas.
The problem is, this "evidence" was from two months ago, and was by no means new, as the Times asserts, and isn't considered evidence, as the Post asserts, even by the "academic" scientists proffering the information.
I believe in the magical invisible oil plume… do you?
Zotero/GMU Update: Judge Dismisses Case
Earlier this month:
A Virginia Circuit Court judge dismissed a lawsuit… against George Mason University's Center for History and New Media.
The lawsuit was, of course, over the Endnote/Zotero dispute between Thompson Reuters and GMU. Here's another related link.
In the early 20th century Edmund Husserl developed a new way of thinking about the world, he called his style of thinking "Phenomenology" as opposed to philosophy or science. Husserl wanted to grasp the phenomena that we encounter from a pre-reflective, pre-scientific point of view. This is because, of course, we have been conditioned by theoretical science to understand phenomena with an outlook that fits nicely with the "world of science and theory." If we follow Husserl, then we will gain access to "the life-world," in German "Lebenswelt."
Here's a cartoon about the practicality of suspending judgment on the validity of science while exploring "the life-world."
Comics and cartoons | Chron.com – Houston Chronicle.
The National Coordinator of Health Information Technology
It seems Obama and the Dems fancy themselves M.D.s, in the Stalinist… I mean "Stimulus" bill (also known as "American Recovery and Reinvestment Act of 2009") they want to track the medical records of every American electronically and then use that information for their own purposes, such as the following:
One new bureaucracy, the National Coordinator of Health Information Technology, will monitor treatments to make sure your doctor is doing what the federal government deems appropriate and cost effective. The goal is to reduce costs and "guide" your doctor's decisions (442, 446). These provisions in the stimulus bill are virtually identical to what Daschle prescribed in his 2008 book, "Critical: What We Can Do About the Health-Care Crisis." According to Daschle, doctors have to give up autonomy and "learn to operate less like solo practitioners."
Hospitals and doctors that are not "meaningful users" of the new system will face penalties. "Meaningful user" isn't defined in the bill. That will be left to the HHS secretary, who will be empowered to impose "more stringent measures of meaningful use over time" (511, 518, 540-541)
What penalties will deter your doctor from going beyond the electronically delivered protocols when your condition is atypical or you need an experimental treatment? The vagueness is intentional. In his book, Daschle proposed an appointed body with vast powers to make the "tough" decisions elected politicians won't make.
The stimulus bill does that, and calls it the Federal Coordinating Council for Comparative Effectiveness Research (190-192). The goal, Daschle's book explained, is to slow the development and use of new medications and technologies because they are driving up costs. He praises Europeans for being more willing to accept "hopeless diagnoses" and "forgo experimental treatments," and he chastises Americans for expecting too much from the health-care system.
Now, if I'm not mistaken, written consent is required before medical documents are disclosed. Also, does the "proletariat" really think that rich white men will have to forgo any treatment whatsoever?
Remember, Daschle would have been Secretary of Health and Human Services if he had paid his taxes. It seems, there is nothing about his anti-American, anti-science, and anti-human-life ideology that Obama disagrees with.
After Election Fact-Checkers Free to Corroborate Einstein's "E=mc²"
Now that no one cares about the contents of Joe the Plumber's trash, it seems more resources can be devoted to boring old Albert Einstein's "E=mc²" formula. It turns out he was right:
PARIS (AFP) — It's taken more than a century, but Einstein's celebrated formula e=mc2 has finally been corroborated, thanks to a heroic computational effort by French, German and Hungarian physicists.
A brainpower consortium led by Laurent Lellouch of France's Centre for Theoretical Physics, using some of the world's mightiest supercomputers, have set down the calculations for estimating the mass of protons and neutrons, the particles at the nucleus of atoms.
According to the conventional model of particle physics, protons and neutrons comprise smaller particles known as quarks, which in turn are bound by gluons.
The odd thing is this: the mass of gluons is zero and the mass of quarks is only five percent. Where, therefore, is the missing 95 percent?
The answer, according to the study published in the US journal Science on Thursday, comes from the energy from the movements and interactions of quarks and gluons.
In other words, energy and mass are equivalent, as Einstein proposed in his Special Theory of Relativity in 1905.
The e=mc2 formula shows that mass can be converted into energy, and energy can be converted into mass.
By showing how much energy would be released if a certain amount of mass were to be converted into energy, the equation has been used many times, most famously as the inspirational basis for building atomic weapons.
That's right folks, Albert Einstein, genius and, lest we forget, war-monger.
Thanks, AFP, for adding the line about Einstein's formula being "the inspirational basis for building atomic weapons" without any further contextual information as to Einstein's political views.
Gibson Limited Edition (Robot?) Guitar
I don't quite know what to think about this new "Robot" guitar. I have a Gibson SG Standard, which I love, and I don't think that adding "robotics" could make it any better. In an age when drum machines and synthesizers fill the air waves and dance halls, it's a shame to see Gibson go techno on us.
Hold the cursor over various areas of the graphic to explore options and info pertaining to the "Robot" SGVodpod videos no longer available.
Come On, Thomson Reuters (EndNote), Don't Be Like That
If you've used "EndNote" (a bibliography resource and information database organization program made by Thomson Reuters), then you may have come across a few annoying "issues" that can make the program less-than satisfying. That's why GMU's Center for History and New Media developed "Zotero." Here's the Wiki description:


text:
Rx only
Each tablet contains methotrexate sodium equivalent to:
Methotrexate . . . . . . . . . . 2.5 mg
Methotrexate is an antimetabolite used in the treatment of certain neoplastic diseases, severe psoriasis, and adult rheumatoid arthritis.
Chemically methotrexate is N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid. The structural formula is:
Methotrexate Tablets for oral administration are available in bottles of 36, bottles of 100, and unit dose cartons of 100 bulers. Methotrexate Tablets contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and the following inactive ingredients: lactose, magnesium stearate, pregelatinized starch NF, sodium hydroxide, and sodium starch glycolate.
Methotrexate inhibits dihydrofolic acid reductase. Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before they can be utilized as carriers of one-carbon groups in the synthesis of purine nucleotides and thymidylate. Therefore, methotrexate interferes with DNA synthesis, repair, and cellular replication. Actively proliferating tissues such as malignant cells, bone marrow, fetal cells, buccal and intestinal mucosa, and cells of the urinary bladder are in general more sensitive to this effect of methotrexate. When cellular proliferation in malignant tissues is greater than in most normal tissues, methotrexate may impair malignant growth without irreversible damage to normal tissues.
The mechanism of action in rheumatoid arthritis is unknown; it may affect immune function. Two reports describe in vitro methotrexate inhibition of DNA precursor uptake by stimulated mononuclear cells, and another describes in animal polyarthritis partial correction by methotrexate of spleen cell hyporesponsiveness and suppressed IL 2 production. Other laboratories, however, have been unable to demonstrate similar effects. Clarification of methotrexate's effect on immune activity and its relation to rheumatoid immunopathogenesis await further studies.
In patients with rheumatoid arthritis, effects of methotrexate on articular swelling and tenderness can be seen as early as 3 to 6 weeks. Although methotrexate clearly ameliorates symptoms of inflammation (pain, swelling, stiffness), there is no evidence that it induces remission of rheumatoid arthritis nor has a beneficial effect been demonstrated on bone erosions and other radiologic changes which result in impaired joint use, functional disability, and deformity.
Most studies of methotrexate in patients with rheumatoid arthritis are relatively short term (3 to 6 months). Limited data from long-term studies indicate that an initial clinical improvement is maintained for at least two years with continued therapy.
In psoriasis, the rate of production of epithelial cells in the skin is greatly increased over normal skin. This differential in proliferation rates is the basis for the use of methotrexate to control the psoriatic process.
In a 6-month double-blind, placebo-controlled trial of 127 pediatric patients with juvenile rheumatoid arthritis (JRA) (mean age, 10.1 years; age range, 2.5 to 18 years; mean duration of disease, 5.1 years) on background non-steroidal anti-inflammatory drugs (NSAIDS) and/or prednisone, methotrexate given weekly at an oral dose of 10 mg/m2 provided significant clinical improvement compared to placebo as measured by either the physician's global assessment, or by a patient composite (25% reduction in the articular-severity score plus improvement in parent and physician global assessments of disease activity). Over two-thirds of the patients in this trial had polyarticular-course JRA, and the numerically greatest response was seen in this subgroup treated with 10 mg/m2/wk methotrexate. The overwhelming majority of the remaining patients had systemic-course JRA. All patients were unresponsive to NSAIDS; approximately one-third were using low dose corticosteroids. Weekly methotrexate at a dose of 5 mg/m2 was not significantly more effective than placebo in this trial.
Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole.
Methotrexate is used in maintenance therapy in combination with other chemotherapeutic agents.
Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma) and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin's lymphomas.
Methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation. It is important to ensure that a psoriasis "flare" is not due to an undiagnosed concomitant disease affecting immune responses.
Methotrexate is indicated in the management of selected adults with severe, active, rheumatoid arthritis (ACR criteria), or children with active polyarticular-course juvenile rheumatoid arthritis, who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose nonsteroidal anti-inflammatory agents (NSAIDs).
Aspirin, NSAIDs, and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of NSAIDs including salicylates has not been fully explored. (See PRECAUTIONS, Drug Interactions.) Steroids may be reduced gradually in patients who respond to methotrexate. Combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine, or cytotoxic agents, has not been studied and may increase the incidence of adverse effects. Rest and physiotherapy as indicated should be continued.
Methotrexate can cause fetal death or teratogenic effects when administered to a pregnant woman. Methotrexate is contraindicated in pregnant women with psoriasis or rheumatoid arthritis and should be used in the treatment of neoplastic diseases only when the potential benefit outweighs the risk to the fetus. Women of childbearing potential should not be started on methotrexate until pregnancy is excluded and should be fully counseled on the serious risk to the fetus (see PRECAUTIONS) should they be come pregnant while undergoing treatment. Pregnancy should be avoided if either partner is receiving methotrexate; during and for a minimum of three months after therapy for male patients, and during and for at least one ovulatory cycle after therapy for female patients. (See BoxedWARNINGS.)
Because of the potential for serious adverse reactions from methotrexate in breast fed infants, it is contraindicated in nursing mothers.
Patients with psoriasis or rheumatoid arthritis with alcoholism, alcoholic liver disease or other chronic liver disease should not receive methotrexate.
Patients with psoriasis or rheumatoid arthritis who have overt or laboratory evidence of immunodeficiency syndromes should not receive methotrexate.
Patients with psoriasis or rheumatoid arthritis who have preexisting blood dyscrasias, such as bone marrow hypoplasia, leukopenia, thrombocytopenia or significant anemia, should not receive methotrexate.
Patients with a known hypersensitivity to methotrexate should not receive the drug.
See Boxed WARNINGS.
Methotrexate formulations and diluents containing preservatives must not be used for intrathecal or high dose methotrexate therapy.
Methotrexate has the potential for serious toxicity. (See Boxed WARNINGS.) Toxic effects may be related in frequency and severity to dose or frequency of administration but have been seen at all doses. Because they can occur at any time during therapy, it is necessary to follow patients on methotrexate closely. Most adverse reactions are reversible if detected early. When such reactions do occur, the drug should be reduced in dosage or discontinued and appropriate corrective measures should be taken. If necessary, this could include the use of leucovorin calcium and/or acute, intermittent hemodialysis with a high-flux dialyzer. (See OVERDOSAGE.) If methotrexate therapy is reinstituted, it should be carried out with caution, with adequate consideration of further need for the drug and with increased alertness as to possible recurrence of toxicity.
The clinical pharmacology of methotrexate has not been well studied in older individuals. Due to diminished hepatic and renal function as well as decreased folate stores in this population, relatively low doses should be considered, and these patients should be closely monitored for early signs of toxicity.
Patients should be informed of the early signs and symptoms of toxicity, of the need to see their physician promptly if they occur, and the need for close follow-up, including periodic laboratory tests to monitor toxicity.
Both the physician and pharmacist should emphasize to the patient that the recommended dose is taken weekly in rheumatoid arthritis and psoriasis, and that mistaken daily use of the recommended dose has led to fatal toxicity. Patients should be encouraged to read the attached Patient Instructions. Prescriptions should not be written or refilled on a PRN basis.
Patients should be informed of the potential benefit and risk in the use of methotrexate. The risk of effects on reproduction should be discussed with both male and female patients taking methotrexate.
Patients undergoing methotrexate therapy should be closely monitored so that toxic effects are detected promptly. Baseline assessment should include a complete blood count with differential and platelet counts, hepatic enzymes, renal function tests, and a chest X-ray. During therapy of rheumatoid arthritis and psoriasis, monitoring of these parameters is recommended: hematology at least monthly, and renal function and liver function every 1 to 2 months. More frequent monitoring is usually indicated during antineoplastic therapy. During initial or changing doses, or during periods of increased risk of elevated methotrexate blood levels (e.g., dehydration), more frequent monitoring may also be indicated.
Transient liver function test abnormalities are observed frequently after methotrexate administration and are usually not cause for modification of methotrexate therapy. Persistent liver function test abnormalities, and/or depression of serum albumin may be indicators of serious liver toxicity and require evaluation. (See PRECAUTIONS; Organ System Toxicity: Hepatic.)
A relationship between abnormal liver function tests and fibrosis or cirrhosis of the liver has not been established for patients with psoriasis. Persistent abnormalities in liver function tests may precede appearance of fibrosis or cirrhosis in the rheumatoid arthritis population.
Pulmonary function tests may be useful if methotrexate-induced lung disease is suspected, especially if baseline measurements are available.
Concomitant administration of some NSAIDs with high dose methotrexate therapy has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and gastrointestinal toxicity.
Caution should be used when NSAIDs and salicylates are administered concomitantly with lower doses of methotrexate. These drugs have been reported to reduce the tubular secretion of methotrexate in an animal model and may enhance its toxicity.
Despite the potential interactions, studies of methotrexate in patients with rheumatoid arthritis have usually included concurrent use of constant dosage regimens of NSAIDs, without apparent problems. It should be appreciated, however, that the doses used in rheumatoid arthritis (7.5 to 15 mg/week) are somewhat lower than those used in psoriasis and that larger doses could lead to unexpected toxicity.
Methotrexate is partially bound to serum albumin, and toxicity may be increased because of displacement by certain drugs, such as salicylates, phenylbutazone, phenytoin, and sulfonamides. Renal tubular transport is also diminished by probenecid; use of methotrexate with this drug should be carefully monitored.
Oral antibiotics such as tetracycline, chloramphenicol, and nonabsorbable broad spectrum antibiotics, may decrease intestinal absorption of methotrexate or interfere with the enterohepatic circulation by inhibiting bowel flora and suppressing metabolism of the drug by bacteria.
Penicillins may reduce the renal clearance of methotrexate; increased serum concentrations of methotrexate with concomitant hematologic and gastrointestinal toxicity have been observed with high and low dose methotrexate. Use of methotrexate with penicillins should be carefully monitored.
The potential for increased hepatotoxicity when methotrexate is administered with other hepatoxic agents has not been evaluated. However, hepatotoxicity has been reported in such cases. Therefore, patients receiving concomitant therapy with methotrexate and other potential hepatotoxins (e.g., azathioprine, retinoids, sulfasalazine) should be closely monitored for possible increased risk of hepatotoxicity.
Methotrexate may decrease the clearance of theophylline; theophylline levels should be monitored when used concurrently with methotrexate.
Certain side effects such as mouth sores may be reduced by folate supplementation with methotrexate.
Trimethoprim/sulfamethoxazole has been reported rarely to increase bone marrow suppression in patients receiving methotrexate, probably by an additive antifolate effect.
No controlled human data exist regarding the risk of neoplasia with methotrexate. Methotrexate has been evaluated in a number of animal studies for carcinogenic potential with inconclusive results. Although there is evidence that methotrexate causes chromosomal damage to animal somatic cells and human bone marrow cells, the clinical significance remains uncertain. Non-Hodgkin's lymphoma and other tumors have been reported in patients receiving low-dose oral methotrexate. However, there have been instances of malignant lymphoma arising during treatment with low-dose oral methotrexate, which have regressed completely following withdrawal of methotrexate, without requiring active anti-lymphoma treatment. Benefits should be weighed against the potential risks before using methotrexate alone or in combination with other drugs, especially in pediatric patients or young adults. Methotrexate causes embryotoxicity, abortion, and fetal defects in humans. It has also been reported to cause impairment of fertility, oligospermia and menstrual dysfunction in humans, during and for a short period after cessation of therapy.
Psoriasis and rheumatoid arthritis: Methotrexate is in Pregnancy Category X. See CONTRAINDICATIONS.
See CONTRAINDICATIONS.
Safety and effectiveness in pediatric patients have been established only in cancer chemotherapy and in polyarticular-course juvenile rheumatoid arthritis.
Published clinical studies evaluating the use of methotrexate in children and adolescents (i.e., patients 2 to 16 years of age) with JRA demonstrated safety comparable to that observed in adults with rheumatoid arthritis. (See CLINICAL PHARMACOLOGY, ADVERSE REACTIONS and DOSAGE AND ADMINISTRATION.)
Clinical studies of methotrexate did not include sufficient numbers of subjects age 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious reflecting the greater frequency of decreased hepatic and renal function, decreased folate stores, concomitant disease or other drug therapy (i.e., that interfere with renal function, methotrexate or folate metabolism) in this population (see Precautions: Drug Interactions). Since decline in renal function may be associated with increases in adverse events and serum creatinine measurements may over estimate renal function in the elderly, more accurate methods (i.e., creatinine clearance) should be considered. Serum methotrexate levels may also be helpful. Elderly patients should be closely monitored for early signs of hepatic, bone marrow and renal toxicity. In chronic use situations, certain toxicities may be reduced by folate supplementation. Postmarketing experience suggests that the occurrence of bone marrow suppression, thrombocytopenia, and pneumonitis may increase with age. See Boxed WARNINGS and Adverse Reactions.
The most frequently reported adverse reactions include ulcerative stomatitis, leukopenia, nausea, and abdominal distress. Other frequently reported adverse effects are malaise, undue fatigue, chills and fever, dizziness and decreased resistance to infection.
Other adverse reactions that have been reported with methotrexate are uled below by organ system. In the oncology setting, concomitant treatment and the underlying disease make specific attribution of a reaction to methotrexate difficult.
Alimentary System: gingivitis, pharyngitis, stomatitis, anorexia, nausea, vomiting, diarrhea, hematemesis, melena, gastrointestinal ulceration and bleeding, enteritis, pancreatitis.
Blood and Lymphatic System Disorders: Suppressed hematopoiesis causing anemia, aplastic anemia, pancytopenia, leukopenia, neutropenia, and/or thrombocytopenia, lymphadenopathy and lymphoproliferative disorders (including reversible). Hypogammaglobulinemia has been reported rarely.
Cardiovascular: pericarditis, pericardial effusion, hypotension, and thromboembolic events (including arterial thrombosis, cerebral thrombosis, deep vein thrombosis, retinal vein thrombosis, thrombophlebitis, and pulmonary embolus).
Central Nervous System: headaches, drowsiness, blurred vision, transient blindness, speech impairment including dysarthria and aphasia, hemiparesis, paresis and convulsions have also occurred following administration of methotrexate. Following low doses, there have been occasional reports of transient subtle cognitive dysfunction, mood alteration, unusual cranial sensations, leukoencephalopathy, or encephalopathy.
Hepatobiliary Disorders: hepatotoxicity, acute hepatitis, chronic fibrosis and cirrhosis, decrease in serum albumin, liver enzyme elevations.
Infection: There have been case reports of sometimes fatal opportunistic infections in patients receiving methotrexate therapy for neoplastic and non-neoplastic diseases. Pneumocystis carinii pneumonia was the most common opportunistic infection. There have also been reports of infections, pneumonia, sepsis, nocardiosis, histoplasmosis, cryptococcosis, Herpes zoster, H. simplex hepatitis, and disseminated H. simplex.
Musculoskeletal System: stress fracture.
Ophthalmic: conjuctivitis, serious visual changes of unknown etiology.
Pulmonary System: respiratory fibrosis, respiratory failure, interstitial pneumonitis deaths have been reported, and chronic interstitial obstructive pulmonary disease has occasionally occurred.
Skin: erythematous rashes, pruritus, urticaria, photosensitivity, pigmentary changes, alopecia, ecchymosis, telangiectasia, acne, furunculosis, erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson Syndrome, skin necrosis, skin ulceration, and exfoliative dermatitis.
Urogenital System: severe nephropathy or renal failure, azotemia, cystitis, hematuria; defective oogenesis or spermatogenesis, transient oligospermia, menstrual dysfunction, vaginal discharge, and gynecomastia; infertility, abortion, fetal defects.
Other rarer reactions related to or attributed to the use of methotrexate such as nodulosis, vasculitis, arthralgia/myalgia, loss of libido/impotence, diabetes, osteoporosis, sudden death, reversible lymphomas, tumor lysis syndrome, soft tissue necrosis and osteonecrosis. Anaphylactoid reactions have been reported.
The approximate incidences of methotrexate attributed (i.e., placebo rate subtracted) adverse reactions in 12 to 18 week double-blind studies of patients (n = 128) with rheumatoid arthritis treated with low-dose oral (7.5 to 15 mg/week) pulse methotrexate, are uled below. Virtually all of these patients were on concomitant nonsteroidal anti-inflammatory drugs and some were also taking low dosages of corticosteroids. Hepatic histology was not examined in these short-term studies. (See PRECAUTIONS.)
Incidence Greater than 10%: Elevated liver function tests 15%, nausea/vomiting 10%.
Incidence 3% to 10%: Stomatitis, thrombocytopenia (platelet count less than 100,000/mm3).
Incidence 1% to 3%: Rash/pruritus/dermatitis, diarrhea, alopecia, leukopenia (WBC less than 3000/mm3), pancytopenia, dizziness.
Two other controlled trials of patients (n = 680) with Rheumatoid Arthritis on 7.5mg - 15mg/wk oral doses showed an incidence of interstitial pneumonitis of 1%. (See PRECAUTIONS.)
Other less common reactions included decreased hematocrit, headache, upper respiratory infection, anorexia, arthralgias, chest pain, coughing, dysuria, eye discomfort, epistaxis, fever, infection, sweating, tinnitus, and vaginal discharge.
There are no recent placebo-controlled trials in patients with psoriasis. There are two literature reports (Roenigk, 1969 and Nyfors, 1978) describing large series (n = 204, 248) of psoriasis patients treated with methotrexate. Dosages ranged up to 25 mg per week and treatment was administered for up to four years. With the exception of alopecia, photosensitivity, and "burning of skin lesions" (each 3% to 10%), the adverse reaction rates in these reports were very similar to those in the rheumatoid arthritis studies. Rarely, painful plaque erosions may appear.
The approximate incidences of adverse reactions reported in pediatric patients with JRA treated with oral, weekly doses of methotrexate (5 to 20 mg/m2/wk or 0.1 to 0.65 mg/kg/wk) were as follows (virtually all patients were receiving concomitant nonsteroidal anti-inflammatory drugs, and some also were taking low doses of corticosteroids): elevated liver function tests, 14%; gastrointestinal reactions (e.g., nausea, vomiting, diarrhea), 11%; stomatitis, 2%; leukopenia, 2%; headache, 1.2%; alopecia, 0.5%; dizziness, 0.2%; and rash, 0.2%. Although there is experience with dosing up to 30 mg/m2/wk in JRA, the published data for doses above 20 mg/m2/wk are too limited to provide reliable estimates of adverse reaction rates.
Leucovorin is indicated to diminish the toxicity and counteract the effect of inadvertently administered overdosages of methotrexate. Leucovorin administration should begin as promptly as possible. As the time interval between methotrexate administration and leucovorin initiation increases, the effectiveness of leucovorin in counteracting toxicity decreases. Monitoring of the serum methotrexate concentration is essential in determining the optimal dose and duration of treatment with leucovorin.
In cases of massive overdosage, hydration and urinary alkalinization may be necessary to prevent the precipitation of methotrexate and/or its metabolites in the renal tubules. Generally speaking, neither hemodialysis nor peritoneal dialysis have been shown to improve methotrexate elimination. However, effective clearance of methotrexate has been reported with acute, intermittent hemodialysis using a high-flux dialyzer (Wall, SM et al: Am J Kidney Dis 28(6): 846-854, 1996).
In postmarketing experience, overdose with methotrexate has generally occurred with oral and intrathecal administration, although intravenous and intramuscular overdose have also been reported.
Reports of oral overdose often indicate accidental daily administration instead of weekly (single or divided doses). Symptoms commonly reported following oral overdose include those symptoms and signs reported at pharmacologic doses, partially hematologic and gastrointestinal reaction. For example, leukopenia, thrombocytopenia, anemia, pancytopenia, bone marrow suppression, mucositis, stomatitis, oral ulceration, nausea, vomiting, gastrointestinal ulceration, gastrointestinal bleeding. In some cases, no symptoms were reported. There have been reports of death following overdose. In these cases, events such as sepsis or septic shock, renal failure, and aplastic anemia were also reported.
Oral administration in tablet form is often preferred when low doses are being administered since absorption is rapid and effective serum levels are obtained.
Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published.1-5 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.
Methotrexate Tablets USP 2.5 mg (contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate)
Yellow, round, scored tablets (Identified 54 323)
NDC 0054-8550-25: Unit dose, 10 tablets per strip, 10 strips per shelf pack, 10 shelf packs per shipper.
NDC 0054-4550-15: Bottles of 36 tablets.
NDC 0054-4550-25: Bottles of 100 tablets.
Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature].
Dispense with a child-resistant closure in a well-closed container as defined in the USP/NF.
Revised February 2007
METHOTREXATE Tablets USP, 2.5 mg
Read the Patient Information that comes with Methotrexate Tablets USP, 2.5 mg before you start using it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your condition or treatment.
Methotrexate is a prescription medicine used in treating certain cancers, severe rheumatoid arthritis including polyarticular juvenile rheumatoid arthritis, and severe psoriasis.
Do not take Methotrexate if:
Before using Methotrexate tell your doctor
Do not:
Methotrexate can cause serious and life-threatening problems including (see "What is the most important information I should know about Methotrexate?"):
The most common side effects of Methotrexate include:
Stop taking Methotrexate and call your doctor right away if you get diarrhea, mouth sores, a fever, dehydration, cough, bleeding, shortness of breath, any signs of infection, or a skin rash. If you have any questions about these or other side effects, talk to your doctor. These are not all the side effects of Methotrexate. Ask your doctor or pharmacist for more information.
General information about Methotrexate
Medicines are sometimes prescribed for conditions other than those described in patient information leaflets. Do not use Methotrexate for a condition for which it was not prescribed. Do not give Methotrexate to other people, even if they have the same symptoms that you have. It may harm them.
This leaflet summarizes the most important information about Methotrexate. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about Methotrexate that is written for healthcare professionals.
For additional information, you may contact Roxane Laboratories at 1-800-962-8364 or at www.roxane.com.
Active Ingredient: Methotrexate contains an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate.
Inactive Ingredients: lactose, magnesium stearate, pregelatinized starch NF, sodium hydroxide, and sodium starch glycolate.